ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO906

BK Virus Seroprevalence in Donors and Kidney Transplant Recipients and Their Correlation with Development of BK Virus Infection in the Post-Transplant Period

Session Information

Category: Transplantation

  • 1802 Transplantation: Clinical


  • Portilla, Andrea, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Mexico
  • Parra, Idalia, Instituto Mexicano del Seguro Social, Guadalajara, jalisco, Mexico
  • Rosado canto, Rodrigo, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Mexico
  • Marino sanchez, José roberto, Instituto Nacional de ciencias médicas Salvador Zubirán, Ciudad de mexico, Mexico
  • Cruz, Cristinoc, INCMNSZ, Mexico, Mexico
  • Cohen-Bucay, Abraham, Boston University Medical Center, Boston, Massachusetts, United States
  • Uribe-uribe, Norma O., Instituto Nacional de Ciencias Medicas y Nutricion, "Salvador Zubiran", Mexico City, Mexico
  • Alberú, Josefina, INCMNSZ, Mexico, Mexico
  • Morales-Buenrostro, Luis E., Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Mexico

BK virus (BKV) nephritis is a common cause of allograft dysfunction, which is related to the level of immunosuppression. Since no specific antiviral treatment is available, predictive markers that could help clinicians personalize the level of immunosuppression given to a specific patient are needed. Aims: to evaluate BKV seroprevalence in kidney donors and recipients as a predictive factor of BKV viruria, viremia and BKV nephritis in the post-transplant period.


BK-IgG ELISA qualitative test (MyBioSource Inc, San Diego, CA), was measured in 169 pts (81 donors and 88 recipients) before kidney transplantation. 76 recipients were followed post-transplant with BKV-PCR in blood and urine at 1, 3, 6, 9, and 12 months after transplantation. In addition, protocol biopsies at 3 and 12 months, and for-cause biopsies due to allograft dysfunction were performed.


58% of donors and 62.5% of recipients were seropositive prior to transplantation. Mean follow-up of transplant recipients was 198 days. They were divided into high risk (D+/R-, n=25) and moderate/low risk (D-/R+, D+/R+ and D-/R-, n=51). Viruria, viremia and BK nephritis developed in 16%, 12%, and 4% in the high risk, and 15.7%, 11.7%, 5.8% in the moderate/low risk group, respectively (p=0.9). Time to development of viruria, viremia, and BKV nephropathy was evaluated with the Kaplan-Meier in both groups and no statistically significance was observed [Figure 1].


BKV seroprevalence in Mexican population was 58.0% in donors and 62.5% in kidney transplant recipients. No correlation was observed between pretransplant serological status of donor and/or recipient and the post-transplant development of BKV viruria, viremia, and nephritis.